IRVINE, Calif. & BELLEVUE, Wash.--(BUSINESS WIRE)-- Vantari Genetics, a full service clinical diagnostics laboratory that also provides esoteric genetic testing and contract research services, and Translational Software®, Inc. (TSI), a leader in the intelligent use of genomic data for clinical decision support, today announced a partnership to provide genotype testing, actionable genomic information and custom reporting in support of the Banner Alzheimer’s Institute’s (BAI) GeneMatch registry. GeneMatch is a ground-breaking national program that leverages genetic testing information to recruit participants for Alzheimer’s prevention studies.

Researchers have identified a number of genes associated with Alzheimer’s disease. The most common form of the disease is called late-onset Alzheimer’s, which usually begins after age 65 and is associated with a gene called apolipoprotein E (APOE.)

Vantari Genetics and TSI are collaborating to support the GeneMatch program by APOE testing and interpreting the cheek swabs of volunteers interested in participating in community-based Alzheimer’s research opportunities. The raw genomic and molecular data from the tests is analyzed to provide scientific intelligence about the genetic variants of volunteers, which is used to identify study participants at varying degrees of genetic risk for developing Alzheimer’s to match them to available research studies.

“We are grateful to be part of a talented, multidisciplinary team supporting a clinical study infrastructure to help the Banner Azheimer’s Institute enroll and genotype volunteers to advance Alzheimer’s research,” stated Shaun Opie, PhD, chief scientific officer at Vantari Genetics.

The companies will work together to provide BAI with in-depth analysis of the APOE data in multiple, customized formats which will be used to help scientists identify early brain changes in participants, and compare the effectiveness of treatments for people with different APOE profiles.

Don Rule, CEO of TSI, commented on the scalability of the company’s platform to cost-effectively provide single gene reporting for clinical trials, and incorporate independent genomic research data. “Our genomic platform is very flexible, which allows us to offer unique genomic testing solutions and data reporting capabilities that can be customized to support single gene testing, in-depth interpretation and analysis, and the integration of independent clinical research,” noted Rule. “We are pleased to be working with Vantari Genetics to support the important work that BAI is doing to help advance the study of genetic risk for Alzheimer’s.”

About Translational Software, Inc.

Translational Software enables healthcare providers to realize the promise of precision medicine. We simplify complex genetic data into evidence-based actionable recommendations to deliver platform agnostic genomic decision support. Our PGx knowledge-base and Fast Healthcare Interoperability Resource (FHIR)-based API has been used to provide over one million PGx recommendations. To learn more visit us at www.TranslationalSoftware.com.

About Vantari Genetics

Vantari is a high complexity, CLIA certified laboratory offering clinical diagnostics, genetic testing, and contract research services across the health spectrum. The company offers a wide range of tests from routine blood and urine chemistry through next-generation sequencing for chromosomal aneuploides, hereditary cancer, and inherited diseases. For more information visit www.vantarigenetics.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171023005310/en/